Last reviewed · How we verify
HDM 12 SQ-HDM
HDM 12 SQ-HDM is a sublingual immunotherapy that desensitizes the immune system to house dust mite allergens through gradual exposure.
HDM 12 SQ-HDM is a sublingual immunotherapy that desensitizes the immune system to house dust mite allergens through gradual exposure. Used for Allergic rhinitis and/or allergic asthma induced by house dust mite allergens.
At a glance
| Generic name | HDM 12 SQ-HDM |
|---|---|
| Also known as | ACARIZAX |
| Sponsor | Clinique Spécialisée en Allergies de la Capitale |
| Drug class | Allergen immunotherapy (sublingual tablet) |
| Target | House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
This is an allergen immunotherapy product designed to reduce allergic responses to house dust mites (HDM) by administering increasing doses of HDM extract sublingually (under the tongue). The mechanism involves immune tolerance induction, shifting the immune response from Th2-mediated allergic inflammation toward Th1/Treg-mediated tolerance, thereby reducing symptoms and medication dependence in HDM-allergic patients.
Approved indications
- Allergic rhinitis and/or allergic asthma induced by house dust mite allergens
Common side effects
- Oral pruritus
- Throat irritation
- Mouth edema
- Local allergic reactions at administration site
Key clinical trials
- A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 (PHASE3)
- Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis
- Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
- A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber (PHASE3)
- Vestibular Versus Sublingual Route of AIT Tablets (PHASE4)
- The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma (PHASE4)
- N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
- Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDM 12 SQ-HDM CI brief — competitive landscape report
- HDM 12 SQ-HDM updates RSS · CI watch RSS
- Clinique Spécialisée en Allergies de la Capitale portfolio CI